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Objective. Thisprospective study wasundertaken toevaluatepregnant women’swillingnesstoundergo HSVtype-speciﬁc serologic
testing andfactorsaﬀectingwillingnessinanobstetrics/gynecology ambulatoryunit.Methods.AtprenatalVisit1,pregnantwomen
(n = 303)withnohistoryofHSV-2were testedforHSV-1/HSV-2beforeandaftertheyreceived counselingongenitalandneonatal
herpes. Results. In both the Unwilling Subgroup and the group that changed from being willing to being unwilling, the most
commonreasonsforchoosingnotto be tested were notbeing at risk forgenital herpes, being testedis too personal, and concern about
what will be done with the results. Of the 134 participants in the Willing/Tested Subgroup, 27 (20%) were HSV-2 seropositive and
81 (60%) were HSV-1 seropositive. Conclusions. These results support the feasibility of HSV serologic testing and counseling in
pregnant women.
1.Introduction
An estimated 45 million people in the United States, includ-
ing approximately 1 in 5 pregnant women (22%), have
genital herpes caused by herpes simplex virus-2 (HSV-2)
[1–3]. HSV-1 infection, also highly prevalent in the United
States, aﬀects approximately two thirds of pregnant women
(63%) [3]. HSV infection in pregnancy is of particular
concern because of one of its most devastating sequelae—
neonatal herpes, which is associated with signiﬁcant neu-
rodevelopmental impairment or death in at least one third
ofinfectedbabies[4].Causedbyintrapartum exposureofthe
fetustoHSV-2or,lessfrequently,HSV-1,neonatalherpeshas
been estimated to aﬀect approximately 1500 infants annually
in theUnitedStatesalthoughrecent ﬁndings suggesta higher
incidence [5–7].
Means of reducing risk of HSV transmission to the
neonate are directed at women with established, symp-
tomatic infection: using antiviral prophylaxis during the last
4 weeks of pregnancy delivering via cesarean section instead
of vaginally and limiting the use of invasive procedures
in women shedding HSV during labor [4, 8]. Because
these strategies do not address prevention of maternal HSV
acquisition during pregnancy or subclinical HSV infections
(∼90% of HSV infections), they prevent only an estimated
20% to 30% of cases of neonatal herpes [9]. The majority
of HSV infections in pregnancy are undiagnosed and are
therefore not addressed by current preventative strategies
[10]. For example, in a recent study of infants born to
252,474 mothers from January 1997 to June 2002 in a
large US managed-care database, a prior diagnosis of HSV
infection had been made in only 12% of mothers who gave
birth to infants with neonatal HSV [6].
Because awareness of maternal HSV status is integral
to eﬀorts to prevent viral transmission to the neonate,
improvement in diagnosis of genital herpes among pregnant
women is warranted. Type-speciﬁc serological tests, which
can detect HSV regardless of whether lesions are present,
constitutethemosteﬀectivemeans ofdiagnosing HSV.Many
experts recommend routine HSV serologic testing during2 Infectious Diseases in Obstetrics and Gynecology
pregnancy [11–15] while others discourage it or do not
practice routine testing on the basis of concerns such as the
negative psychological impact of HSV testing and lack of
cost-eﬀectiveness [9, 16–20]. The current prospective study
was undertaken to evaluate pregnant women’s willingness to
undergoHSVtype-speciﬁc serologictesting, factorsaﬀecting
their willingness, and the feasibility of HSV serologic testing
and counseling in an obstetrics/gynecology ambulatory unit.
2.Materialsand Methods
2.1. Sample. Pregnant women at least 18 years old and at
15 ± 3 weeks of gestation were eligible for the study if
they did not have a known history of HSV-2 infection. All
participants provided written informed consent.
2.2. Procedures. An institutional review board approved the
protocol for this prospective study conducted at a single
study center in the Department of Obstetrics and Gyne-
cology and Reproductive Medicine Health Science Center
at the State University of New York at Stony Brook (Stony
Brook, NY, USA). The study included two oﬃce visits,
Visit 1 (the ﬁrst prenatal visit; Figure 1)a n dV i s i t2 .A t
Visit 1, the study was described to patients. Patients were
told that the study (1) involved their willingness to have a
blood test to determine whether they were infected with the
virus that causes genital herpes and the virus that causes
cold sores and (2) would require a time commitment of
approximately1 hour at this visit and, possibly, an additional
20-minute oﬃcevisitthenext week.Those providing written
informed consent to participate in the study were asked
to complete a questionnaire on demographics and baseline
clinical information.
Blood was drawn for testing for HSV-1/HSV-2 from
consenting participants via the FOCUS HerpeSelect 1 and
2 ELISA assay. Using a standardized script (the appendix),
health care providers then counseled participants about
genital herpes, its risks to the neonate, and the signiﬁcance
of positive and negative serologic tests for genital herpes.
These participants, the Willing/Tested Subgroup, were asked
to complete two brief, self-administered questionnaires
addressing their understanding of the information presented
during counseling and their satisfaction with counsel-
ing, respectively. Questionnaire items assessing participants’
understanding were declarative statements about herpes
with response options of true or false. Questionnaire items
assessing participants’ satisfaction with various aspects of
counseling had response options of very satisﬁed, satisﬁed,
neutral, dissatisﬁed,o rvery dissatisﬁed.
Participants unwilling to be tested (the Unwilling Sub-
group) were asked to complete a questionnaire addressing
barriers to serologic testing. Questionnaire items, which
corresponded to speciﬁc potential reasons for being unwill-
ing to be tested, had multiple-choice response options:
strongly disagree, disagree, agree,a n dstrongly agree.H e a l t h
care providers then counseled them about genital herpes
with the same standardized script described above (the
appendix). After they were counseled, participants were
again asked if they were willing to be tested. If they agreed
and provided informed consent, they were given the blood
test. If they remained unwilling to be tested, they were
asked to complete the questionnaire addressing barriers
to serologic testing again and to complete the two self-
administered questionnaires addressing participants’ under-
standing oftheinformationpresentedduringcounselingand
their satisfaction with counseling, respectively.
At Visit 2, which occurred approximately 1 week after
Visit 1, participants who were serologically tested at Visit 1
were counseled about the resultsof theirtest and encouraged
to discuss the results with their partners. Participants who
were HSV-2 seropositive were also provided with an educa-
tional brochure on reducing risk of transmission of genital
herpes and were asked if they were willing to take medicine
to treat their herpes during pregnancy. Both seropositive and
seronegative participants were given two self-administered
questionnaires, adapted to participants’ serostatus, that
addressed their understanding of the information presented
during counseling and their satisfaction with counseling,
respectively.
2.3. Measures and Data Analysis. The primary endpoint was
the percentage of participants who expressed willingness
to be tested for HSV-1 and HSV-2 and who provided a
blood sample. Other endpoints included the percentages of
participants in the Unwilling Subgroup expressing particular
reasons for being unwilling to be tested, HSV-1 and HSV-2
seroprevalence among those who provided a blood sample,
responses to questions on the counseling questionnaires in
the Willing/Tested Subgroup compared with the Unwilling
Subgroup, the percentage of HSV-2 seropositive participants
willing toacceptantiherpestherapyduringpregnancy,health
care providers’ ratings of the median time spent counseling
participants, and the specialty of the health care provider
who counseled participants.
Some participants initially expressed a willingness to be
tested for HSV but later became unwilling to be tested and
declined to provide a blood sample. These participants were
categorized as being unwilling to be tested and included
in the Unwilling Subgroup. In post hoc summaries, reasons
for not being tested and responses on the counseling
questionnairesweresummarized separatelyfortheUnwilling
Subgroup and the portion of this subgroup that changed
from being willing to being unwilling.
All data were summarized with descriptive statistics. In
addition, the Willing/Tested Subgroup was compared with
the Unwilling Subgroup on demographic variables and
sexual history with chi-square or Fisher’s Exact tests and
on responses to the counseling questionnaires with Fisher’s
Exact tests.
3.Results
3.1. Sample. T h es a m p l ec o m p r i s e d3 0 4w o m e nw h oc o n -
sentedtoparticipateinthestudy.Demographicsandbaseline
clinical characteristics are described in Table 1.P a r t i c i p a n t s ’
mean (SD) age was 29.3 (6.2) years. The majority (87%) of
participants were white, 8% were black, and the remainderInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Demographics and sexual history.
Sample
(N = 304)
Subgroup willing to be tested
(n = 134)
Subgroup unwilling to be tested
(n = 169)
Age, mean (SD), years 29.3 (6.2) 29.3 (6.1) 29.3 (6.3)
Race, %
White 87 84 91
Black 87 8
Asian 57 2
Type of insurance,∗ %
Medicare 0 0 0
Medicaid 16 10 21
Private/employer-provided 83 89 79
None <1 <10
Marital status,∗ %
Single, living alone 52 8
Single, living with partner 25 23 27
Single, living with roommates/parents 10 11 9
Married 59 65 54
Divorced 10 2
Widowed 00 0
Employment status, %
Full time 40 39 41
Part Time 24 21 27
Unemployed 14 14 14
Homemaker/housewife 16 16 15
Full-time student 57 2
Other 34 3
Highest level of education, %
Elementary <10 1
High school 31 28 34
Some college 32 29 34
Technical/other professionalschool 55 4
College 20 22 18
Postgraduate 12 16 9
2004 household pretax income, %
<$20,000 17 14 20
$20,000 to $39,999 26 29 23
$40,000 to $59,999 23 18 26
$60,000 to $79,999 13 15 12
$80,000 to $99,999 10 12 9
≥$100,000 10 12 9
A g ea tﬁ r s ts e x u a li n t e r c o u r s e ,%
15 or younger 20 19 20
16 or older 80 81 80
Estimated # of sexual partners, %
1 17 19 15
2t o4 43 40 47
5t o9 24 25 24
10 to 19 13 13 13
20 to 29 12 <1
30 to 39 <1 <11
∗P<. 05 for subgroup willing to be tested versus subgroup not willing to be tested.4 Infectious Diseases in Obstetrics and Gynecology
Study is described to patients
Willing patients sign general
informed consent
Participants are asked if
they are willing to have blood drawn
Participants complete questionnaire on
demographics and risk factors
Participants complete questionnaire
about barriers to testing
Participants receive counseling
Participants have blood drawn
Participants receive counseling
The next visit is scheduled
on the usual prenatal schedule
Participants complete barriers
to testing questionnaire again
Visit 2 is scheduled for
1week later
Participants complete questionnaires
on understanding of and
satisfaction with counseling
Participants complete questionnaires
on understanding of and
satisfaction with counseling
Willing to be tested
(participants who provide informed
consent for blood test)
∗ If yes, then the path for “willing to be tested” was followed.
No
Participants are asked again
if they are willing to be tested∗
Unwilling to be tested
(participants who do not give informed
consent for blood test)
Figure 1: Study procedures for Visit 1.
was of Asian heritage. Approximately two thirds (64%) of
participants were employed part or full time, and most
women(83%)reported havingprivateoremployer-provided
health insurance. None of the participants reported a history
of genital herpes infection, human immunodeﬁciency virus
(HIV) infection, or a rash or viral illness since their last
menstrual period.The majorityofparticipants (82%to92%,
depending on the symptom) reported 0 episodes in the past
6 months of genital itching or redness, burning or tingling
around genitals, thighs, or buttocks, pain with urination,
discharge with urination, or vaginal discharge not associated
with other symptoms.
Three hundred and four (304) women enrolled in the
study and were included in demographic summaries. How-
ever, the analyses on willingness to be tested and summaries
of questionnaire responses were based on data from 303Infectious Diseases in Obstetrics and Gynecology 5
women because 1 participant enrolled butprematurely with-
drew before providing evaluable data on the questionnaires
or willingness to be tested.
3.2. Willingness to Be Tested for HSV-2. At Visit 1, 134 of 303
participants (44%) were willing to be tested for HSV-1/HSV-
2 and provided a blood sample (Willing/Tested Subgroup),
and 169 (56%) were unwilling to be tested (Unwilling
Subgroup). Although 249 of 303 participants (82%) initially
indicated that they were willing to be tested, 115 (38% of
the sample) changed from willing to unwilling and did not
provide blood samples at Visit 1. Participants had to go
to another location to get their blood drawn, and it was
not part of their routine prenatal blood workup. These 115
participantswereincludedintheUnwillingSubgroup.Ofthe
participants initially unwilling to be tested, only 2 changed
frombeingunwilling tobeingwillingaftercounselingatVisit
1. The number of patients never willing to be tested was 52.
The Willing/Tested Subgroup did not diﬀer from the
Unwilling Subgroup with respect to most demographic vari-
ablesor sexual history (Table 1).However,those willing to be
tested were more likely than those unwilling to be tested to
be married (65% versus 54%) and to have private/employer-
provided health insurance (89% versus 79%) (P<. 05 for
frequency distributions of responses for marital status and
insurance type) (Table 1).
InboththeUnwillingSubgroupandthe52patientsnever
willing to be tested, the most common reason for choosing
not to be tested was not being at risk for genital herpes
(Table 2). In both the Unwilling Subgroup and the group
of participants who changed from being willing to being
unwilling, the most common reasons for choosing not to be
tested were not being at risk for genital herpes, being tested is
too personal,a n dconcern about what will be done with the
results (data not shown). Proportionally more participants
who changed from willing to unwilling than participants
in the Unwilling Subgroup as a whole cited these reasons
for not wanting to be tested (% participants who strongly
agreed/agreed: 85% versus 90% for not at risk, 53% versus
63% for being tested is too personal, and 51% versus 60% for
concern about what will be done with the results)( d i ﬀerences
notstatisticallytested).Thefrequencydistributionofreasons
for choosing not to be tested did not diﬀer as a function of
whether participants were asked about testing before or after
they received counseling (data not shown).
3.3. HSV Seroprevalence. Of the 134 participants in the
Willing/Tested Subgroup, 27 (20%) were HSV-2 seropositive
and 81 (60%) were HSV-1 seropositive (Table 3). The
percentages of participants testing both HSV-1 and HSV-2
positive, both HSV-1 and HSV-2 negative, HSV-1 positive
andHSV-2negative, and HSV-1negative andHSV-2positive
were 11%, 31%, 49%, and 9%, respectively (Table 3).
3.4. Counseling. The median time commitment for counsel-
ing the blood draw on Visit 1 for participants who consented
to the blood draw was 30 minutes per participant (range 20
to 35 minutes). Counseling was provided by a nurse for 70%
of participants, by an obstetrician/gynecologist for 26%, and
by another health care provider for 4%.
Visit 1. Participants’ understanding of the information from
counseling at Visit 1 was generally good (Table 4). The
majority of participants answered each question correctly.
Nevertheless, 15% of participants incorrectly answered that
you cannot spread herpes to your newborn at the time of
delivery. Results did not diﬀer between the Willing/Tested
Subgroup and the Unwilling Subgroup (Table 4) or between
the latter subgroups and those who changed from willing to
unwilling to be tested (data not shown).
Nearly all participants (≥99%) indicated that they were
satisﬁed or very satisﬁed with each of the probed aspects of
counseling. Resultsdid not diﬀer between the Willing/Tested
Subgroup and the Unwilling Subgroup.
Visit 2. Participants’ understanding of counseling infor-
mation from Visit 2 was generally good regardless of
serostatus (Table 4). The majority of participants answered
each question correctly. Among participants who were
HSV-2 seropositive, 100% agreed that it is important to
use medicine to treat herpes during pregnancy, and all
were willing to take a medicine during the last 4 weeks of
pregnancy to treat herpes. Nearly all participants (≥99%)
indicated that they were satisﬁed or very satisﬁed with each
of the probed aspects of counseling.
4.Discussion
Previous studies involving patient surveys suggest that
pregnant women perceive the value of prenatal screening for
genitalherpes and are willing tobe tested[21,22].This study
extends previous ﬁndings by being the ﬁrst to determine
whether participants who express a willingness to be tested
also agree to provide a blood sample for serologic testing,
to assess barriers to testing, and to assess demographic and
clinical correlates of willingness and unwillingness to be
tested. In this study conductedin a US obstetrics/gynecology
ambulatory unit, 44% of 303 women who were given the
opportunity to be tested for HSV-1/HSV-2 agreed to be
tested and provided a blood sample at their ﬁrst prenatal
visit. These women agreed to be tested and provided a
blood sample prior to receiving any counseling or other
information from the practice about genital or neonatal
herpes;theyweresimplyaskedwhethertheywouldbewilling
to have a blood test to determine if they were infected with
the virus that causes genital herpes or the virus that causes
cold sores.
Among the 56% of participants unwilling to be tested
for HSV, the most common reasons for being unwilling to
be tested were not being at risk for genital herpes (85%),
being tested is too personal (53%), and concern about what
will be done with the results (51%). Substantial proportions
of this Unwilling Subgroup also cited other reasons for
being unwilling including test would take too much time
(34%), d on o tw a n tt ok n o wr e s u l t s(31%), fear of results
(27%), having to tell my partner (24%), and no beneﬁt6 Infectious Diseases in Obstetrics and Gynecology
Table 2: Summary of precounseling reasons for choosing not to be tested for HSV-2 on Visit 1. Data are expressed as (%) of participants.
Subgroup changing
from willing to unwilling
(n = 115)
Subgroup unwilling to
be tested
(n = 169)
Subgroup never willing
(n = 52)
Cost of the test n = 72 n = 126 n = 52
Strongly disagree/disagree 100 99 67
Agree/strongly agree 0 1 33
Fear of results n = 72 n = 126 n = 52
Strongly disagree/disagree 77 73 69
Agree/strongly agree 23 27 31
Knowing is not important to me n = 72 n = 126 n = 52
Strongly disagree/disagree 99 89 77
Agree/strongly agree 1 11 23
Concern about what will be done with
results n = 72 n = 126 n = 52
Strongly disagree/disagree 40 49 59
Agree/strongly agree 60 51 41
No knowledge of genital herpes n = 72 n = 126 n = 52
Strongly disagree/disagree 100 95 95
Agree/strongly agree 0 5 10
No knowledge of how genital herpes
will aﬀect my baby n = 72 n = 126 n = 52
Strongly disagree/disagree 100 98 96
Agree/strongly agree 0 2 4
Not at risk for genital herpes n = 71 n = 125 n = 52
Strongly disagree/disagree 9 15 22
Agree/strongly agree 91 85 78
No beneﬁt to ﬁnding out results n = 72 n = 126 n = 52
Strongly disagree/disagree 75 78 82
Agree/strongly agree 25 22 18
Test would take too much time n = 72 n = 126 n = 52
Strongly disagree/disagree 4 66 92
Agree/strongly agree 53 34 8
Being tested is too personal n = 72 n = 125 n = 51
Strongly disagree/disagree 34 47 65
Agree/strongly agree 66 53 35
Having to tell my partner the test
results n = 72 n = 126 n = 52
Strongly disagree/disagree 83 66 65
Agree/strongly agree 17 24 35
to ﬁnding out results (22%). The Unwilling Subgroup did
not diﬀer from those willing to be tested with respect to
sexual history or demographic variables such as age, race,
pretax income, or highest level of education. However, those
willing to be tested were signiﬁcantly more likely than
those unwilling to be tested to be married and to have
private/employer-provided health insurance. These reasons
for and demographic correlates of being unwilling to be
testeddonotpointtospeciﬁcissuesorfactorsthatdetermine
the majority of participants’ willingness or unwillingness to
be tested for HSV nor do they suggest a particular proﬁle
of the individual willing or unwilling to be tested. Rather,
the data are consistent with the presence of heterogeneous,
patient-speciﬁc determinants of willingness to be tested for
HSV among pregnant women.
The proportion of the sample that actually provided a
blood sample for determination of HSV serostatus (44%)
was substantially lower than that initially indicating a
willingness to be tested for HSV (82%). With those who
initially were willing to be tested but changed to unwilling as
with the Unwilling Subgroup as a whole, the most common
reasons for being unwilling to be tested included not being
at risk for genital herpes (90% of those providing reasons
for being unwilling), being tested is too personal (63%), andInfectious Diseases in Obstetrics and Gynecology 7
Table 3: HSV seroprevalence. Data are expressed as number (%) of
participants.
N = 134
H S V - 1p o s i t i v e 8 1( 6 0 )
H S V - 2p o s i t i v e 1 5( 1 9 )
HSV-1/HSV-2 combinations
HSV-1 positive and HSV-2 positive 15 (11)
HSV-1 positive and HSV-2 negative 66 (49)
H S V - 1n e g a t i v ea n dH S V - 2p o s i t i v e 1 2( 9 )
H S V - 1n e g a t i v ea n dH S V - 2n e g a t i v e 4 1( 3 1 )
concern about what will be done with the results (60%). As
only 71 or 72 (depending on the reason) of 115 participants
who changed from willing to unwilling provided reasons
for being unwilling, these data may be unrepresentative
and should be interpreted cautiously. Whether aspects of
the study protocol aﬀected willingness to provide a blood
sample is not known. Participants had to go to another
location to get their blood drawn, and it was not part
of their routine prenatal blood workup. The latter factors
may have inﬂuenced willingness to provide a blood sample.
In addition, the questionnaire included several items on
presence of baseline genitourinary signs and symptoms such
as genital itching or redness, burning or tingling around
genitals, thighs, or buttocks, pain with urination, discharge
with urination, and vaginal discharge. Most participants
reported absence of these symptoms. Possibly, the absence
of these symptoms contributed to participants’ perception
of not being at risk from genital herpes and suggested to
them that they would not beneﬁt from serologic testing.
In addition, participants had to go to another location to
get their blood drawn, and it was not part of their routine
prenatal blood workup. These factors may also have aﬀected
willingness to be tested.
Although participants generally showed good under-
standing and retention of the information imparted during
counseling,being counseledaboutgenitalherpes and neona-
tal herpes appears not to have been eﬀective in motivating
participants who were initially unwilling to be tested to
change their minds: only 2 of those initially unwilling to
be tested decided to have their blood tested after the brief
counseling session. The counseling did not aﬀect the reasons
for being unwilling to be tested: the frequency of citing
reasons for being unwilling to be tested did not diﬀer as a
functionofwhetherornotparticipantshadreceivedcounsel-
ing. The counseling may have been ineﬀective because it did
not address some of the most common reasons for not being
willing to be tested: being tested is too personal and concern
about what will be done with the results.T h ec o u n s e l i n g
information was speciﬁc to genital herpes and its potential
eﬀects on the neonate; it did not include information on
conﬁdentiality or other aspects of disposition of the test
results. Perhaps inclusion of such information would be
useful in reducing unwillingness to be tested, a possibility
that warrants further study.
HSV-2 seroprevalence in this sample from a single
obstetrics/gynecology ambulatory unit was 20%, a result
consistent with the prevalence of HSV-2 in US women
generally and with US population-based data showing HSV-
2 seroprevalence of 22% among pregnant women [1–3].
Likewise, the HSV-1 seropositivity rate of 60% in this study
is consistent with the US population rate of 63% [3]. None
of the women who tested positive for HSV-2 were aware
of their HSV-2 serostatus prior to enrollment in the study.
(Awareness ofprior HSV-1serostatuswas not assessed inthis
study.)This ﬁnding, which corroboratesthepreviousﬁnding
that the majority of HSV-2 infections remain undiagnosed
[1,2],highlightstheimportanceofimprovingawareness and
recognition of genital herpes among pregnant women. That
all women who tested positive for HSV-2 agreed that it is
important to use medicine to treat herpes during pregnancy
and were willing to take a medicine during the last 4 weeks
of pregnancy to treat herpes suggests that women aware of
their seropositive status will implement measures to reduce
the risk of transferring the virus to their infants.
Importantly, 31% of population was seronegative for
both HSV-1 and HSV-2 and therefore susceptible to getting
primary genital herpes during pregnancy. The majority
of neonatal HSV infections occur among infants born to
women experiencing primary HSV infections. The risk of
neonatal infection is particularly high when the mother con-
tractsaprimaryornonprimaryﬁrst episodeofgenitalherpes
late in gestation [23]. These considerations underscore the
importance of education of women and their partners about
the prevention of acquisition of HSV during pregnancy.
5.Conclusions
Results of this study corroborate previous ﬁndings on the
high prevalence of HSV seropositivity among pregnant
women and support the feasibility of HSV serologic testing
andcounseling inthispopulation.Furtherresearch isneeded
on methods of counseling patients about HSV and neonatal
herpes and on speciﬁc information that should be included
in counseling materials.
Appendix
CounselingScriptforVisit 1
What Is Genital Herpes?
(i) Genital herpes is a virus that is spread through
intimate, skin-to-skin contact, including vaginal,
oral, or anal sex.
(ii) The genital herpes virus can be active on the surface
of the skin with symptoms and a visible outbreak or
without any visible signs or symptoms.
(iii) Therearemanysymptomsthatcanbeassociatedwith
the virus such as itching, redness, bumps, tingling,
and cuts in the genital area/boxer short area.8 Infectious Diseases in Obstetrics and Gynecology
Table 4: Summary of the Understanding Counseling Questionnaire. Data are expressed as (%) of participants answering the true/false
questions correctly.
Sample
(N = 303)
Subgroup
willing to be
tested
(n = 134)
Subgroup
unwilling to
be tested
(n = 169)
Visit 1
Genital herpes is a contagious virus spread by intimate skin-to-skin contact. 95 94 96
Genital herpes is a very common disease. 97 >99 96
You cannot spread herpes to your newborn at the time of delivery. 85 85 86
Even if you have genital herpes, it is still possible to have a healthy baby. 97 97 97
There is no test you can take to ﬁnd out if you have the virus. 95 94 95
T h e r ei sn oc u r ef o rg e n i t a lh e r p e s . (n = 302)
86 87 (n = 168)
85
H S V - 1( t h ec o l ds o r ev i r u s )c a nc a u s eg e n i t a lh e r p e s . 7 0 6 8 7 1
Visit 2 HSV seronegative participants (n = 107)
Genital herpes cannot be spread by intimate skin-to-skin contact. 86
Genital herpes can be active without any visible signs or symptoms of an outbreak. 98
If you get genital herpes late in your pregnancy, your baby will have a high risk of
getting herpes.
86
Even though you have tested negative, it is still possible that your partner has
genital herpes.
100
You can reduce your risk of getting herpes by practicing safer sex. 100
If your partner has genital herpes, he can take medicine to treat his herpes and
reduce the risk of spreading it to you.
95
If you get HSV-1 (the cold sore virus) genital infection during your pregnancy, you
c a np a s si to nt oy o u rb a b y .
75
Visit 2 HSV seropositive participants (n = 27)
Herpes is less commonthan diabetes or asthma. 92
Once diagnosed, it is diﬃcult to know how long you have had genital herpes. 96
Genital herpes can be treated to reduce the risk of having outbreaks. 100
You cannot spread genital herpes to your newborn at the time of delivery. 85
There are things you can do to reduce the risk of spreading genital herpes to your
b a b ya tt h et i m eo fd e l i v e r y .
100
Genital herpes can be cured. 88
If you get HSV-1 (the cold sore virus) genital infection during your pregnancy, you
c a np a s si to nt oy o u rb a b y .
81
(iv) It is possible that what you think are yeast infections,
urinary tract infections, or vaginal discharge actually
may be cases of genital herpes.
(v) Remember, there is no cure for herpes. However
treatment options are available to treat this disease.
Who Has Genital Herpes?
(i) One in ﬁve Americans over the age of 14 has the
genital herpes virus, that is approximately 45 million
people.
(ii) And when you consider that among American adults
who have the genital herpes virus, 9 out of 10 (40
million) do not even know they have it.
(iii) Anyone who is sexually active—even with just one
person—can get GH; there are up to one million new
cases each year.
( i v )Y o um a yw a n tt oﬁ n do u ti fy o u rs y m p t o m sa r e
actually what you think they are.
Why Is It Important to the Pregnant Woman?
(i) If you have the genital herpes virus, you are at a risk
of spreading herpes to your newborn at the time of
delivery.
What Are the Risks to the Baby?
(i) If the baby gets the herpes virus, also called neonatal
herpes, the baby usually gets sick during the ﬁrst one
to two weeks of life.Infectious Diseases in Obstetrics and Gynecology 9
(ii) This illness can cause mental and physical disabilities
and in the worst cases death.
(iii) But remember even if you have genital herpes, you
can still have a healthy a baby.
(iv) There are things that you can do to reduce the risks
to your baby, but ﬁrst you need to know if you have
the genital herpes virus.
What Is the Purpose of a Blood Test for Genital Herpes?
(i) As mentioned, the ﬁrst step is to take the test so that
you are aware of whether or not you have herpes.
(ii) If you take the test today, at your next visit we will be
able to tell you the results of the test.
(iii) Even if you think you do not have the virus, it is
important to take the test to determine that you in
fact do not have herpes, then you can take steps to
reduce the risk of getting herpes, especially during
your pregnancy.
What Does It Mean If My Test Is Negative?
(i) If your test shows that you are negative, you do not
have herpes but if you were only recently exposed
(within the last 3 months) a repeat test may be
needed.
(ii) It also means that it is important for you to take steps
tokeepfromgettingthevirusduringyourpregnancy:
(a) know if your partner is infected,
(b) practice safer sex including use of condoms.
What Does It Mean If My Test Is Positive?
(i) If your test shows that you are positive, you do have
herpes.
(ii) As with any medical test, there is a small chance
the positive result is a false positive. If you need to
conﬁrm the results, there are diﬀerent tests that can
be done.
(iii) Remember, genital herpes is more common than
diseases like diabetes and asthma. So if you have
herpes, you are not alone, and you should not feel
embarrassed or ashamed.
(iv) If you do have this virus, there are things you can do
for yourself and your baby.
What Is the Importance of the Cold Sore Virus (HSV-1)?
(i) HSV-1 (the cold sore virus) can also cause a genital
herpes infection by being spread during oral-genital
sex.
(ii) Women who have HSV-1 have little to no risk for
spreading HSV-1 to their baby because they have
developedprotectiveantibodiestothisvirusthatthey
pass to their baby.
(iii) If you do not have HSV-1, it is important for you
to take steps to keep from getting HSV-1 during
pregnancy:
(a) know if your partner has HSV-1,
(b) abstain from oral-genital sex during your preg-
nancy.
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